News
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a mini-rally that extended into Friday; the company's share price added nearly 5% ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results